Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-974-5 | CAS number: 12047-11-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Justification for type of information:
- The study did not follow any guidelines, but it provides precious infornmation on the substance toxicity profile.
Data source
Reference
- Reference Type:
- publication
- Title:
- Experimental pneumoconiosis due to inspiration of barium ferrite powder
- Author:
- Kosova LV, Gersovic EM
- Year:
- 1 972
- Bibliographic source:
- Gig Tr Prof Zabol. 16 (5): 41-4
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Powder of test substance was administrated to male rats by inhalation route for a period of 9 months.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Barium ferrite
- IUPAC Name:
- Barium ferrite
- Details on test material:
- Description of test material reported by authors is rappresentative of the barium hexaferrite.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- not specified
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- Initial body weight of animals were about 130 g.
Administration / exposure
- Route of administration:
- inhalation: dust
- Type of inhalation exposure:
- whole body
- Vehicle:
- air
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 9 months.
- Frequency of treatment:
- 4 h/day every day
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
10 mg/m3
Basis:
no data
- Remarks:
- Doses / Concentrations:
30 mg/m3
Basis:
no data
- Remarks:
- Doses / Concentrations:
200 mg/m3
Basis:
no data
- Remarks:
- Doses / Concentrations:
400 mg/m3
Basis:
no data
- No. of animals per sex per dose:
- 24 rats/males/10 mg/m3
24 rats/males/30 mg/m3
24 rats/males/200 mg/m3
24 rats/males/400 mg/m3 - Control animals:
- no
Examinations
- Observations and examinations performed and frequency:
- hematic parameters was monitored one time a month.
- Sacrifice and pathology:
- The parameters evalutaed for establishing of potential toxicity of barium hexaferrite powder were body weight, hemoglobin values in the blood, hematocrite, glucose concentration, chloride, hydrogen sulfide groups, hypoxia, alkali reserve, peroxydase activity, catalase activity, cholinesterase activity and transaminase activity. Every organ was examinated for ascorbic acid content, further in lung collagen content was determined. After sacrifice all tissues were collected and subjected to hystological examination.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No differences were observed
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Significant variations of hematologic values were not registered, however an increase of enzimatic activity was observed.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Ascorbic acid and collagen in lungs were increased in animals exposed to higher concentrations while no differences were observed for other animals.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Heart, liver, spleen and kidneys did not present any significant alteration. Into the lung tissue hotbeds of cells and powder were evidenced in small conglomerates or isolated.
- Details on results:
- Based on provision and distribution of hotbeds of cells and powder could be established that repeated exposure to high concentration (200-400 mg/m3 for 9 months) of barium hexaferrite caused pneumoconiosis by inhalation route. After exposure to 10-30 mg/m3 of barium hexaferrite an accumulation of powder and cells containing powder were observed in alveolus and on alveolar pariets. For smaller concentrations of barium hexaferrite hotbeds to the initial state were shown. By means of coloration with silver nitrated a small net of argyrophil fibers was observed, it suggest a minor cellular reaction.
Effect levels
open allclose all
- Dose descriptor:
- NOEC
- Effect level:
- < 10 mg/m³ air
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: The critical effect is considered the pneumoconiosis.
- Dose descriptor:
- NOAEC
- Effect level:
- 30 mg/m³ air
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: The critical effect is considered the pneumoconiosis.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- In conclusion the inhalation of barium hexaferrite powder may cause fibrogenic activity in the lungs inducing pneumoconiosis. The rate of fibrogenic process is related to the powder concentration; a NOAEC of 30 mg/m3 is identified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.